Table 1.
The characterization of DOX-LTSL-CREKA (n=3)
Formulation | Size (nm) | PDI | Zeta potential (mV) | Entrapment efficiency (%) |
---|---|---|---|---|
DOX-LTSL | 85.6±2.7 | 0.18±0.03 | −3.67±0.09 | 98.98±0.66 |
DOX-LTSL-CREKA | 83.8±3.4 | 0.19±0.03 | −5.96±0.09 | 99.03±0.63 |
Abbreviations: DOX, doxorubicin; LTSL, lysolipid-containing thermosensitive liposome; CREKA, Cys-Arg-Glu-Lys-Ala; PDI, polydispersity index.